미국의 백혈병 치료제 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 치료법별, 유통 채널별, 부문별 예측(2025-2033년)

U.S. Leukemia Therapeutics Market Summary

The U.S. leukemia therapeutics market size was estimated at USD 7.23 billion in 2024 and is projected to reach USD 13.07 billion by 2033, growing at a CAGR of 6.80% from 2025 to 2033. The industry is expanding due to the strong adoption of targeted therapies that offer high clinical precision.

Increased use of genomic profiling supports accurate treatment selection and enhances overall therapeutic outcomes. Growth in CAR-T cell therapy utilization adds momentum through improved remission durability in high-risk patients. Advancements in bispecific antibodies strengthen options for relapsed and refractory cases. For instance, in March 2024, the National Cancer Institute (via the Surveillance, Epidemiology, and End Results Program) reported that in the U.S., there were an estimated 536,245 people living with leukemia in 2022, representing the prevalence of the disease. The broader integration of molecular diagnostics enhances patient identification for advanced therapies. Continuous development of next-generation agents sustains momentum in the market. The rising preference for personalized oncology care is expected to strengthen long-term treatment demand.

Therapeutic innovation strengthens market growth as clinical pipelines deliver novel mechanisms for acute and chronic leukemia. Wider availability of oral targeted agents improves adherence and supports strong commercial performance. Expansion of clinical evidence enhances prescriber confidence across major oncology networks. Increased survival rates create ongoing demand for maintenance and follow-up therapies. High disease burden within aging populations drives treatment initiation across multiple leukemia types. Advancements in combination regimens have improved the depth of response in both frontline and salvage settings. For instance, in November 2025, Business Wire reported that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Leukogene Therapeutics Inc.'s lead product candidate LTI-214 (also named M2T-CD33) for the treatment of Acute Myeloid Leukemia (AML), providing incentives such as tax credits on qualified clinical trial costs, waiver of certain FDA fees, and U.S. market exclusivity upon approval. Strong investment from major pharmaceutical companies accelerates the development and commercialization of new agents.

Improved treatment access through specialized oncology centers contributes to market expansion across the U.S. Growth in real-world evidence supports broader adoption of immunotherapy and targeted strategies. Higher utilization of high-value biologics strengthens revenue contribution across leading manufacturers. Enhanced therapeutic durability reduces the frequency of relapse and encourages continued long-term therapy. Rising clinical trial activity in major cancer institutions supports rapid evaluation of emerging platforms. An increased emphasis on precision treatment pathways supports the consistent uptake of advanced therapeutics. Continuous improvements in patient management practices reinforce sustained demand for leukemia treatments.

U.S. Leukemia Therapeutics Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. leukemia therapeutics market report based on type, treatment, and distribution channels:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Chronic Myeloid Leukemia (CML)
• Chronic Lymphocytic Leukemia (CLL)
• Acute Lymphocytic Leukemia (ALL)
• Acute Myeloid Leukemia (AML)
• Others
• Treatment Outlook (Revenue, USD Million, 2021 - 2033)
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Others
• Distribution Channels Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacy
• Retail Pharmacy
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Treatment
  • 1.2.3. Distribution Channels
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Leukemia Therapeutics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. U.S. Leukemia Therapeutics Market: Type Business Analysis

• 4.1. Type Market Share, 2024 & 2033
• 4.2. Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 4.4. Chronic Myeloid Leukemia (CML)
  • 4.4.1. Chronic Myeloid Leukemia (CML) Market, 2021 - 2033 (USD Million)
• 4.5. Chronic Lymphocytic Leukemia (CLL)
  • 4.5.1. Chronic Lymphocytic Leukemia (CLL) Market, 2021 - 2033 (USD Million)
• 4.6. Acute Lymphocytic Leukemia (ALL)
  • 4.6.1. Acute Lymphocytic Leukemia (ALL) Market, 2021 - 2033 (USD Million)
• 4.7. Acute Myeloid Leukemia (AML)
  • 4.7.1. Acute Myeloid Leukemia (AML) Market, 2021 - 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. U.S. Leukemia Therapeutics Market: Treatment Business Analysis

• 5.1. Treatment Market Share, 2024 & 2033
• 5.2. Treatment Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by treatment, 2021 to 2033 (USD Million)
• 5.4. Chemotherapy
  • 5.4.1. Chemotherapy Market, 2021 - 2033 (USD Million)
• 5.5. Targeted Therapy
  • 5.5.1. Targeted Therapy Market, 2021 - 2033 (USD Million)
• 5.6. Immunotherapy
  • 5.6.1. Immunotherapy Market, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. U.S. Leukemia Therapeutics Market: Distribution Channels Business Analysis

• 6.1. Distribution Channels Market Share, 2024 & 2033
• 6.2. Distribution Channels Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by distribution channels, 2021 to 2033 (USD Million)
• 6.4. Hospital Pharmacy
  • 6.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Million)
• 6.5. Retail Pharmacy
  • 6.5.1. Retail Pharmacy Market, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. Novartis
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Roche / Genentech
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. AbbVie
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Bristol-Myers Squibb (BMS)
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Pfizer
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Amgen
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Johnson & Johnson (Janssen)
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Gilead Sciences (Kite Pharma)
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. AstraZeneca
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. Sanofi
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives